fbpx Yourgene Health plc - Home
previous arrow
next arrow
Slider

Please find below the latest news from Yourgene Health. We also share this news across social media networks.

  • 5 November 2020 - Directorate change +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Directorate change
    Chief Scientific Officer appointment to drive new product development roadmap

    Manchester, UK – 5 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the appointment of Dr. Joanne Mason as Chief Scientific Officer as a director of the Company with immediate effect.

    Dr Mason has been director of Research & Development (non-board position) at Yourgene since joining the Company in December 2019,

    Read More
  • 3 November 2020 - Partnership with Take2 Health Limited +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Partnership with Take2 Health Limited
    Yourgene to run genomic test for Nasopharyngeal Carcinoma (NPC) Screening in Taiwan

    Manchester, UK – 3 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its wholly-owned subsidiary, Yourgene Health Taipei, has signed a regional marketing and services agreement (the “Agreement”) with Hong Kong based Take2 Health Limited (“Take2”), to promote Take2’s clinically-validated genomic test for Nasopharyngeal Carcinoma

    Read More
  • 26 October 2020 - Half-year Trading update +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Half-year Trading update
    H1 year-on-year growth demonstrating the resilience of the Company

    Manchester, UK – 26 October 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the half-year ended 30 September 2020 (“H1 2020”).

    Revenues for the half-year ended 30 September 2020 were £8.2m (H1 2019: £7.8m), up 5% compared to the previous year, with strong European revenues offsetting the

    Read More
  • 23 October 2020 - CQC registration +

    Yourgene Health plc
    (“Yourgene Health” or the "Company")

    CQC registration

    Manchester, UK – 23 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received notification from the Care Quality Commission (“CQC”) that the Company’s facilities at Citylabs 1.0 in Manchester are now a second registered location from which to perform diagnostics and screening procedures.

    The extension of the Company’s current CQC registration allows NIPT testing greater flexibility to operate

    Read More
  • 21 October 2020 - Yourgene Genomic Services collaboration with Cytox +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Yourgene Genomic Services collaboration with Cytox

    Partnership with Cytox to enable clinical access to genoSCORE™ - a new genetic test to determine the risk of developing Alzheimer’s disease

    Manchester, UK – 21 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces a new collaboration between the recently launched Yourgene Genomic Services (“YGS”) and Cytox Ltd (“Cytox”), for a beta-testing genomic study on their

    Read More
  • 12 October 2020 - Elucigene DPYD tests to be used routinely in Wales +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Elucigene DPYD tests to be used routinely in Wales

    Wales is first UK nation to offer DPYD screening to patients undergoing chemotherapy
    DPYD tests screen patients to identify risk of severe side effects from certain chemotherapy treatments

    Manchester, UK – 12 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its oncology product, Elucigene DPYD test, is now being used in Wales to routinely

    Read More
  • 8 October 2020 - Strategic reproductive health partnership secured in Japan +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Strategic reproductive health partnership secured in Japan

    Manchester, UK – 8 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces it has entered into a 5-year strategic partnership with a blue chip Japanese multinational to provide Yourgene’s Flex™ Analysis Software (“ Flex Software”) bioinformatics platform for a reproductive health project.

    Yourgene and the Japanese partner (the “Partner”) have entered into a technology transfer

    Read More
  • 7 October 2020 - IONA® Nx awarded contract with St George’s NHS Hospital +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    IONA ® Nx awarded contract with St George’s NHS Hospital

    Manchester, UK – 7 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded the contract for non-invasive prenatal testing (NIPT) using its newly-launched IONA ® Nx NIPT Workflow ('IONA ® Nx'), by the prestigious St George’s NHS Trust Foundation in Tooting, South London (“St George’s”). The contract, subject to signing by both

    Read More
  • 28 September 2020 - Launch of Yourgene Genomic Services +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Launch of Yourgene Genomic Services

    Manchester, UK – 28 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of Yourgene Genomic Services, an integration and expansion of the Company’s international service laboratory offerings. Yourgene Genomic Services becomes a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations.

    Yourgene Genomic Services (“YGS”) will bring together

    Read More
  • 24 September 2020 - DPD reimbursement in Germany +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    DPD reimbursement in Germany

    Manchester, UK – 24 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the German Federal Joint Committee, G-BA, the national reimbursement authority in Germany, has approved the reimbursement for testing of Dihydropyrimidine Dehydrogenase (DPD) deficiency in Germany, which opens up the clinical market in this region for the Company’s first oncology genotyping product, the Elucigene DPYD Test. The

    Read More
  • 22 September 2020 - AGM statement +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    AGM Statement

    Manchester, UK – 22 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be holding its Annual General Meeting (AGM) at 4:00pm today.

    At the meeting, Adam Reynolds, Non-executive Chairman, will make the following statement:

    I am delighted to welcome longstanding and recent shareholders to our AGM. Whilst the pandemic has presented serious challenges to individuals, communities and businesses worldwide, these are

    Read More
  • 21 September 2020 - US distribution agreement for DPYD and other products +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    US distribution agreement for DPYD and other products

    Manchester, UK – 21 September 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has appointed Immuno-Biological Laboratories Inc (‘IBL-America’), a supplier of in-vitro diagnostic kits for the medical device and research industry, as a non-exclusive distributor for several PCR (‘polymerase chain reaction’) tests across Yourgene’s reproductive health and oncology portfolios in the US.

    The

    Read More
  • 3 September 2020 - IONA® Nx Launch +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    IONA ® Nx Launch

    Manchester, UK – 3 September 2020:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the launch of IONA ® Nx NIPT workflow, the Company’s new innovative non-invasive prenatal test (‘NIPT’). The IONA Nx seeks to offer clinical labs a high performing, flexible, scalable and innovative NIPT service in-house and is developed to run on the Illumina Nextseq 550 Dx platform for next generation

    Read More
  • 13 August 2020 - TGA approves IONA® Nx for sale in Australia +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    TGA approves IONA ® Nx for sale in Australia

    Manchester, UK – 13 August 2020:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its IONA ® Nx NIPT workflow (‘IONA ® Nx’), a non-invasive prenatal test (‘NIPT’), has been approved by Australia’s Therapeutics Goods Association (‘TGA’) as a medical device Class 3, allowing Southern Cross Diagnostics, Yourgene’s Australian distributor, to commence sales.

    The TGA is the regulatory

    Read More
  • 5 August 2020 - Result of Placing +

    Yourgene Health plc

    (“Yourgene” or the “Group” or the “Company”)

    Result of Placing

    Manchester, UK – 5 August 2020:  Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group, is pleased to confirm, further to the announcements made yesterday and earlier today, that all allocations have been confirmed by Nplus1 Singer Capital Markets Limited ( "N+1 Singer" ), and the Company  has raised gross proceeds of £16.15 million (approximately £15.0 million net of expenses) through a Placing of

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Pregnant lady sitting at table with Laptop

Media & Investor Relations
Walbrook PR Ltd
4 Lombard Street
London
EC3V 9HD
yourgene@walbrookpr.com
T : +44 (0)20 7933 8780

Two business people looking at computer screen